Beta-Lactone Compounds Inhibit ClpP Protease to Reduce Bacterial Virulence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics face challenges in effectively inhibiting the activity of pathogenic bacteria and protozoa, particularly drug-resistant strains, and there is a need for compounds that target virulence factors rather than viability to reduce the risk of resistance development.
Innovation Solution
Development of beta-lactone compounds that specifically inhibit the bacterial protease ClpP, thereby interfering with virulence pathways in Gram-positive bacteria and protozoa, including the use of these compounds as antibacterial and antiprotozoal agents to suppress virulence and prevent biofilm formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then bacterial infections can be treated, but drug-resistant strains develop and viability is targeted leading to resistance
Solution Approach 1:
The patent extracts the target from bacterial viability and focuses on virulence factors specifically. By identifying and inhibiting ClpP protease as a key virulence factor rather than targeting essential viability functions, the invention enables treatment of infections while avoiding selection for resistance in essential bacterial processes.
Solution Approach 2:
The patent changes the target parameter from bacterial viability to virulence factor activity. By shifting the therapeutic target to ClpP protease activity rather than essential cellular functions, the invention achieves effective treatment while minimizing selective pressure for resistance development.
2Reliability
If antibiotics target cellular functions for infection treatment, then infections are treated, but the number and breadth of therapeutic targets is limited
Solution Approach 1:
The patent segments the bacterial cell functions into essential viability functions and non-essential virulence functions. By targeting only the virulence segment (ClpP protease) rather than essential cellular functions, the invention expands therapeutic breadth without compromising bacterial survival, thereby reducing resistance pressure.
Solution Approach 2:
The patent uses ClpP protease as an intermediary target between bacterial infection and host pathology. By inhibiting this specific virulence factor rather than directly attacking bacterial viability, the invention achieves effective treatment while maintaining bacterial viability, thus expanding therapeutic versatility.
3Object-generated harmful factors
If ClpP inhibitors are developed to target virulence factors, then virulence is reduced and resistance is minimized, but such inhibitors have not been previously disclosed
Solution Approach 1:
The patent converts the previously harmful effect of ClpP protease activity (which promotes virulence and biofilm formation) into a beneficial target for inhibition. By designing compounds that specifically inhibit ClpP, the invention transforms a virulence factor into a therapeutic target, reducing harmful effects while minimizing resistance development.
Data Source
AI summary
The present invention relates to specific beta-lactone compounds and compositions thereof for the treatment of infections, such as, e.g., infections with bacteria or infections with protozoa, in particular infections with Gram-positive and/or Gram-negative bacteria and of infectious diseases caused by or related to Gram-positive and/or Gram-negative bacteria, and to the modulation of virulence of Gram-positive and/or Gram-negative bacteria or of protozoa by specific beta-lactone compounds. The invention further relates to the use of the compounds or compositions for preventing or eliminating biofilms.